COMPASS Pathways Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
156
- Stock Symbol
-
CMPS
- Investments
-
2
- Share Price
-
$8.06
- (As of Friday Closing)
COMPASS Pathways General Information
Description
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Contact Information
Website
www.compasspathways.comCorporate Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Corporate Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
COMPASS Pathways Timeline
COMPASS Pathways Stock Performance
As of 20-Nov-2026, COMPASS Pathways’s stock price is $8.06. Its current market cap is $1.14B with 142M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.06 | $8.65 | $4.88 - $15.87 | $1.14B | 142M | 3.07M | -$2.35 |
COMPASS Pathways Financials Summary
As of 30-Sep-2026, COMPASS Pathways has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,343,985 | 511,765 | 84,231 | 326,089 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (275,294) | (292,784) | (157,084) | (119,861) |
| Net Income | (266,301) | (287,862) | (155,122) | (118,464) |
| Total Assets | 519,096 | 210,349 | 213,666 | 275,987 |
| Total Debt | 54,394 | 35,035 | 32,193 | 33,050 |
COMPASS Pathways Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
COMPASS Pathways Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
COMPASS Pathways Comparisons
Industry
Financing
Details
COMPASS Pathways Competitors (8)
One of COMPASS Pathways’s 8 competitors is AtaiBeckley, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AtaiBeckley | Formerly VC-backed | New York, NY | ||||
| Silo Wellness | Corporation | Toronto, Canada | ||||
| Revive Therapeutics | Corporation | Toronto, Canada | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Definium Therapeutics | Formerly VC-backed | New York, NY |
COMPASS Pathways Patents
COMPASS Pathways Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026220029-A1 | Pyrrolidine-indole compounds and compositions comprising the same which are modulators of 5- ht2a | Pending | 17-Apr-2025 | ||
| US-20260327205-A1 | C-linked pyrrolidine-indole compounds and compositions comprising the same | Pending | 11-Apr-2025 | ||
| WO-2026215478-A1 | Pyrrolidine-indole compounds as 5-ht2a receptor agonists | Pending | 11-Apr-2025 | ||
| US-20260021070-A1 | Subcutaneous formulations comprising psilocybin derivatives | Pending | 19-Jul-2024 | ||
| WO-2026017869-A1 | Subcutaneous formulations comprising psilocybin derivatives | Pending | 19-Jul-2024 | A61K9/0019 |
COMPASS Pathways Signals
COMPASS Pathways Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
COMPASS Pathways Investments (2)
COMPASS Pathways’s most recent deal was a Corporate Asset Purchase with Compass Pathways (Intellectual Property Asset Portfolio). The deal was made on 14-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Compass Pathways (Intellectual Property Asset Portfolio) | 14-Sep-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Delix Therapeutics | 06-Mar-2020 | Corporate | Drug Discovery |
COMPASS Pathways ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
COMPASS Pathways Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Compass Pathfinder Holdings | Altrincham, United Kingdom | 2017 |
COMPASS Pathways FAQs
-
When was COMPASS Pathways founded?
COMPASS Pathways was founded in 2016.
-
Where is COMPASS Pathways headquartered?
COMPASS Pathways is headquartered in Altrincham, United Kingdom.
-
What is the size of COMPASS Pathways?
COMPASS Pathways has 156 total employees.
-
What industry is COMPASS Pathways in?
COMPASS Pathways’s primary industry is Biotechnology.
-
Is COMPASS Pathways a private or public company?
COMPASS Pathways is a Public company.
-
What is COMPASS Pathways’s stock symbol?
The ticker symbol for COMPASS Pathways is CMPS.
-
What is the current stock price of COMPASS Pathways?
As of 20-Nov-2026 the stock price of COMPASS Pathways is $8.06.
-
What is the current market cap of COMPASS Pathways?
The current market capitalization of COMPASS Pathways is $1.14B.
-
Who are COMPASS Pathways’s competitors?
AtaiBeckley, Silo Wellness, Revive Therapeutics, Minerva Neurosciences, and Definium Therapeutics are some of the 8 competitors of COMPASS Pathways.
-
What is COMPASS Pathways’s annual earnings per share (EPS)?
COMPASS Pathways’s EPS for 12 months was -$2.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process